Renewed global threat by the novel SARS-CoV-2 variants ‘XBB, BF.7, BQ.1, BA.2.75, BA.4.6’: A discussion

Mohapatra, Ranjan K.; Mahal, Ahmed; Kutikuppala, LV Simhachalam; Pal, Madhumita; Kandi, Venkataramana; Sarangi, Ashish K.; Obaidullah, Ahmad J.; Mishra, Snehasish

doi:10.3389/fviro.2022.1077155

Cited by 17 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the combination of multiple mutations in the Omicron's sub variants has more profound effect on the binding a nity indicating increased antibody resistance. This effect was clearly detected in the possible next dominant new subvariants BM.1.1.1, BA.2.3.20 and CH.1.1 (Orthrus) [35] and Table 2. Furthermore, and to test our method, we examined some experimentally evaluated mutations in residues P337, R346, G339, and S371 that are located in the S309 epitope and once more our computational method was compatible with the experimental results (Table 2).…”

Section: Discussionmentioning

confidence: 80%

In silico evaluation of anti SARS-CoV-2 antibodies neutralization power: A blueprint with monoclonal antibody Sotrovimab

Ashoor

Marzouq

Fathallah

2023

Preprint

View full text Add to dashboard Cite

Immune escape caused by genetic variations of SARS-CoV-2 S protein immunogenic epitopes affects the efficiency of monoclonal antibody-based therapy of COVID-19. Therefore, predicting the effects of these variations on immune escape is important to adapt rapidly anti SARS-CoV-2 Mab therapy. We herein describe a computational method to evaluate the neutralizing power a monoclonal antibody specific of a given SARS-CoV-2 variant and to compare it to its potential neutralizing power of others and emergent variants. The method’s calls for building in silico complex between the spike protein of a SARS-CoV-2 variant and a neutralizing antibody, analyzing the molecular interactions pattern and calculating the binding energy. This data is assigned a neutralizing value of 100% to which can be compared the neutralization value of any SARS-CoV-2 variant determined after molecular replacement in the complex of the RBD sequence with the RBD of this variant. Application of this method to the class 3 neutralizing antibody Sotrovimab and 24 variants and subvariants showed that the affinity binding and neutralizing power, decreased gradually with new variants. This method is of interest to adapt the use of therapeutic antibodies to the treatment of emerging variants. It could be applied to antibody-based treatment of other viral infections.

show abstract

Section: Discussionmentioning

confidence: 80%

In silico evaluation of anti SARS-CoV-2 antibodies neutralization power: A blueprint with monoclonal antibody Sotrovimab

Ashoor

Marzouq

Fathallah

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The continuous vigilance, reporting and comparative analyses of the genomic sequences of the various Omicron sub-lineages are also crucial in understanding how this pathogen evolves, which would help in designing effective prevention and control strategies to limit the spread of the ongoing COVID-19 pandemic. [99,100]…”

Section: Strategies For Infection Controlmentioning

confidence: 99%

“…The implementation of adequate prevention and control measures and designing newer vaccine strategies are the priority requirements to counter SARS‐CoV‐2 infections caused by Omicron, other variants and variants of future. The continuous vigilance, reporting and comparative analyses of the genomic sequences of the various Omicron sub‐lineages are also crucial in understanding how this pathogen evolves, which would help in designing effective prevention and control strategies to limit the spread of the ongoing COVID‐19 pandemic [99,100] …”

Section: Strategies For Infection Controlmentioning

confidence: 99%

The SARS‐CoV‐2 Omicron Variant and its Multiple Sub‐lineages: Transmissibility, Vaccine Development, Antiviral Drugs, Monoclonal Antibodies, and Strategies for Infection Control – a Review

Mohapatra¹,

Verma

Ramana

et al. 2023

ChemistrySelect

Self Cite

View full text Add to dashboard Cite

The Omicron (B.1.1.529), fifth variant of concern (VOC) of SARS-CoV-2, initially identified following a steep increase in COVID-19 cases in Southern Africa in November 2021. It is a highlymutated variant and is more contagious as compared with the Delta variant, however less deadly. Due to its high transmission rate, it spreads dramatically, and causing huge surges worldwide. It causes "mild infection", with hospitalisations less likely to occur. However, this variant is known to show resistance to neutralizing antibodies (nAbs) generated through vaccination and/or prior infection as well as to monoclonal antibodies (mAbs) used to treat COVID-19 patients. In many countries, booster doses of vaccines have been recommended to increase the protective levels of antibodies in vaccinated individuals. Along with the implementation of appropriate prevention and control strategy measures, current efforts are also focussed on the development of better vaccines and mAbs to counter this variant. This review highlights the global health concerns and challenges posed by the Omicron variant and present an update on its sub-lineages.

show abstract

“…There are a lot of competitions to develop, manufacture, market, and approve biologics and biosimilars globally. The COVID-19 pandemic demanded even monoclonal antibodies (mAbs), e.g., tocilizumab, sarilumab, and itolizumab, as therapeutics [ 6 , 7 , 8 , 9 ]. As a silver lining in the dark cloud, the pandemic has marked the turning point for Indian pharmaceuticals to put its best foot forward.…”

Section: Introductionmentioning

confidence: 99%

Indian Biosimilars and Vaccines at Crossroads–Replicating the Success of Pharmagenerics

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background: The global pharma sector is fast shifting from generics to biologics and biosimilars with the first approval in Europe in 2006 followed by US approval in 2015. In the form of Hepatitis B vaccine, India saw its first recombinant biologics approval in 2000. Around 20% of generic medications and 62% of vaccines are now supplied by the Indian pharmaceutical industry. It is this good position in biologics and biosimilars production that could potentially improve healthcare via decreased treatment cost. India has witnessed large investments in biosimilars over the years. Numerous India-bred new players, e.g., Enzene Biosciences Ltd., are keen on biosimilars and have joined the race alongside the emerging giants, e.g., Biocon and Dr. Reddy’s. A very positive sign was the remarkable during the COVID-19 pandemic by Bharat Biotech and the Serum Institute of India. India’s biopharmaceutical industry has been instrumental in producing and supplying preventives and therapeutics to fight COVID-19. Despite a weak supply chain and workforce pressure, the production was augmented to provide reasonably priced high-quality medications to more than 133 nations. Biosimilars could cost-effectively treat chronic diseases involving expensive conventional therapies, including diabetes, respiratory ailments, cancer, and connective tissue diseases. Biologics and biosimilars have been and are being tested to treat and manage COVID-19 symptoms characterized by inflammation and respiratory distress. Purpose of review: Although India boasts many universities, research centers, and a relatively skilled workforce, its global University–Industry collaboration ranking is 24, IPR ranking remains 47 and innovation ranking 39. This reveals a wide industry-academia gap to bridge. There are gaps in effective translational research in India that must be promptly and appropriately addressed. Innovation demands strong and effective collaborations among universities, techno-incubators, and industries. Methodology: Many successful research findings in academia do not get translation opportunities supposedly due to low industrial collaboration, low IP knowledge, and publication pressure with stringent timelines. In light of this, a detailed review of literature, including policy papers, government initiatives, and corporate reviews, was carried out, and the compilation and synthesis of the secondary data were meticulously summarized for the easy comprehension of the facts and roadmap ahead. For easy comprehension, charts, figures, and compiled tables are presented. Results: This review assesses India’s situation in the biosimilar space, the gaps and areas to improve for Indian investment strategies, development, and innovation, addressing need for a more skilled workforce, industrial collaboration, and business models. Conclusions: This review also proposes forward an approach to empowering technopreneurs to develop MSMEs for large-scale operations to support India in taking innovative thoughts to the global level to ultimately realize a self-reliant India. The limitations of the compilation are also highlighted towards the end.

show abstract

Renewed global threat by the novel SARS-CoV-2 variants ‘XBB, BF.7, BQ.1, BA.2.75, BA.4.6’: A discussion

Cited by 17 publications

References 26 publications

In silico evaluation of anti SARS-CoV-2 antibodies neutralization power: A blueprint with monoclonal antibody Sotrovimab

In silico evaluation of anti SARS-CoV-2 antibodies neutralization power: A blueprint with monoclonal antibody Sotrovimab

The SARS‐CoV‐2 Omicron Variant and its Multiple Sub‐lineages: Transmissibility, Vaccine Development, Antiviral Drugs, Monoclonal Antibodies, and Strategies for Infection Control – a Review

Indian Biosimilars and Vaccines at Crossroads–Replicating the Success of Pharmagenerics

Contact Info

Product

Resources

About